SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen

Pharmacogenomics

Volumn 12, Issue 11, 2011, Pages 1535-1543

  Moyer, Ann M ^a   Suman, Vera J ^a   Weinshilboum, Richard M ^a   Avula, Rajeswari ^a   Black, John L ^a   Safgren, Stephanie L ^a   Kuffel, Mary J ^a   Ames, Matthew M ^a   Ingle, James N ^a   Goetz, Matthew P ^a  

^a MAYO CLINIC   (United States)

Author keywords

breast cancer; copy number polymorphism; CYP2C19; pharmacogenomic; polymorphism; single nucleotide; SULT1A1; tamoxifen

Indexed keywords

AMIODARONE; CIMETIDINE; CYTOCHROME P450 2C19; DNA; DOXEPIN; FLUOXETINE; HALOPERIDOL; PARAFFIN; PAROXETINE; SERTRALINE; SULFOTRANSFERASE 1A1; TAMOXIFEN; TICLOPIDINE;

AGED; ARTICLE; BREAST CANCER; COHORT ANALYSIS; DISEASE FREE SURVIVAL; EARLY CANCER; FEMALE; GENE DOSAGE; GENE FREQUENCY; GENOTYPE; HUMAN; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; MONOTHERAPY; NUCLEOTIDE SEQUENCE; POSTMENOPAUSE; PROGNOSIS; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; ARYL HYDROCARBON HYDROXYLASES; ARYLSULFOTRANSFERASE; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; DNA COPY NUMBER VARIATIONS; FEMALE; FOLLOW-UP STUDIES; GENETIC ASSOCIATION STUDIES; HUMANS; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; TAMOXIFEN;

EID: 80455174466     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.97     Document Type: Article

References (35)

1. Early Breast Cancer Trialists Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-1717 (2005).
2. Johnson MD, Zuo H, Lee KH et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res. Treat. 85, 151-159 (2004).
3. Lien EA, Anker G, Lonning PE, Solheim E, Ueland PM. Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. Cancer Res. 50, 5851-5857 (1990).
4. Lien EA, Solheim E, Lea OA, Lundgren S, Kvinnsland S, Ueland PM. Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res. 49, 2175-2183 (1989).
5. Lien EA, Solheim E, Ueland PM. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res. 51, 4837-4844 (1991).
6. Stearns V, Johnson MD, Rae JM et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl Cancer Inst. 95, 1758-1764 (2003).
7. Nishiyama T, Ogura K, Nakano H et al. Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases. Biochem. Pharmacol. 63, 1817-1830 (2002).
8. Ogura K, Ishikawa Y, Kaku T et al. Quaternary ammonium-linked glucuronidation of trans-4-hydroxytamoxifen, an active metabolite of tamoxifen, by human liver microsomes and UDP-glucuronosyltransferase 1a4. Biochem. Pharmacol. 71, 1358-1369 (2006).
9. Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome p450 system in vitro: prominent roles for CYP3A and CYP2D6. J. Pharmacol. Exp. Ther. 310, 1062-1075 (2004).
10. Jin Y, Desta Z, Stearns V et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl Cancer Inst. 97, 30-39 (2005).
11. Wu X, Hawse JR, Subramaniam M, Goetz MP, Ingle JN, Spelsberg TC. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor a for degradation in breast cancer cells. Cancer Res. 69, 1722-1727 (2009).
12. Kiyotani K, Mushiroda T, Sasa M et al. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci. 99, 995-999 (2008).
13. Lash TL, Lien EA, Sorensen HT, Hamilton-Dutoit S. Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol. 10, 825-833 (2009).
14. Leyland-Jones B, Regan MM, Bouzyk M et al. Outcome according to CYP2D6 genotype among postmenopausal women with endocrine-responsive early invasive breast cancer randomized in the BIG 1-98 trial. Cancer Res. 70, (Abstracts S1-S8) (2011).
15. Rae JM, Drury S, Hayes DF et al. Lack of correlation between gene variants in tamoxifen metabolizing enzymes with primary endpoints in the ATAC trial. Cancer Res. 70, (Abstracts S1-S7) (2010).
16. Schroth W, Antoniadou L, Fritz P et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J. Clin. Oncol. 25, 5187-5193 (2007).
17. Schroth W, Goetz MP, Hamann U et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302, 1429-1436 (2009).
18. Serrano D, Lazzeroni M, Zambon CF et al. Efficacy of tamoxifen based on cytochrome p450 2D6, CYP2C19 and SULT1A1 genotype in the italian tamoxifen prevention trial. Pharmacogenomics J 11, 100-107 (2011).
19. Wegman P, Vainikka L, Stal O et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res. 7, R284-R290 (2005).
20. Xu Y, Sun Y, Yao L et al. Association between CYP2D6*10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann. Oncol. 19, 1423-1429 (2008).
21. Wegman P, Elingarami S, Carstensen J, Stal O, Nordenskjold B, Wingren S. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res. 9, R7 (2007).
22. Gnant M, Mlineritsch B, Stoeger H et al. Mature results from ABCSG-12: adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zolendronic acid, in premenopausal women with endocrine-responsive early breast cancer. J. Clin. Oncol. 28 (Abstract 533) (2010).
23. Nowell S, Sweeney C, Winters M et al. Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy. J. Natl Cancer Inst. 94, 1635-1640 (2002).
24. Sim SC, Risinger C, Dahl ML et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin. Pharmacol. Ther. 79, 103-113 (2006).
25. Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br. J. Clin. Pharmacol. 69, 222-230 (2010).
26. Gjerde J, Geisler J, Lundgren S et al. Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. BMC Cancer 10, 313 (2010).
27. Hebbring SJ, Adjei AA, Baer JL et al. Human SULT1A1 gene: copy number differences and functional implications. Hum. Mol. Genet. 16, 463-470 (2007).
28. Grabinski JL, Smith LS, Chisholm GB et al. Genotypic and allelic frequencies of SULT1A1 polymorphisms in women receiving adjuvant tamoxifen therapy. Breast Cancer Res. Treat. 95, 13-16 (2006).
29. Ingle JN, Suman VJ, Mailliard JA et al. Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group trial 89-30-52. Breast Cancer Res. Treat. 98, 217-222 (2006).
30. Goetz MP, Knox SK, Suman VJ et al. The impact of cytochrome p450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat. 101, 113-121 (2007).
31. Goetz MP, Rae JM, Suman VJ et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. 23, 9312-9318 (2005).
32. Schroth W, Goetz MP, Hamann U et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302, 1429-1436 (2009).
33. Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EM. Metabolism of tamoxifen by recombinant human cytochrome p450 enzymes: formation of the 4-hydroxy, 4-hydroxy and N-desmethyl metabolites and isomerization of trans-4- hydroxytamoxifen. Drug Metab. Dispos. 30, 869-874 (2002).
34. Justenhoven C, Hamann U, Pierl CB et al. CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res. Treat. 115, 391-396 (2009).
35. Murdter TE, Schroth W, Bacchus-Gerybadze L et al. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of Phase I and II enzymes on their concentration levels in plasma. Clin. Pharmacol. Ther. 89, 708-717 (2011).